Alex's Lemonade Stand Foundation for Childhood Cancer

Patients with relapsed neuroblastoma and osteosarcoma have limited therapeutic options and frequently die of their disease. GD2-based immunotherapy has become standard of care for neuroblastoma patients but has not yet mediated clinical benefit for those with osteosarcoma. Additionally, a large percentage of neuroblastoma patients who receive anti-GD2 immunotherapy eventually relapse. Therefore, there is a need to improve immunotherapy to benefit more patients.